Trading Signals: TGTX Stock Price Prediction and Forecast (Mon. Aug. 10, 2015 - Wed. Sep. 14, 2022)(TG Therapeutics Inc)
| TGTX latest price $26.1650 (0.29%) ($25.7050 - $26.4600) on Tue. Oct. 27, 2020. | |
| | Trend Analysis and Forecast | | | Average Daily Percentage Swing | 3.74% (three month average) | RSI | 27 | Latest Price | $26.1650(0.29%) | Stocks Behave Similarly | Similar Stock List | Daily Trend | TGTX declines -1.8% a day on average for past five trading days. | Weekly Trend | TGTX declines -6.7% a week on average for past two weeks. | Market Behavior | Value stocks sell-off for large cap. Value stock sell-off for small cap. | Correlated ETFs | Broad market will support TGTX advance at 0% a week (0% probability) XBI(64%) ARKG(59%) ARKK(56%) IWO(56%) IBB(55%) | Factors Impacting TGTX price | TGTX will decline at least -1.87% in a week (0% probabilities). VIXM(-37%) VXX(-33%) UUP(-18%) DRIV(-3%) TBT(-2%) | | | | | Relative Volatility | (options are extremely cheap) | | | Market Trend Strength | -1.87% (StdDev 3.74%) | Hourly BBV | -0.5 () | Intraday Trend | 0% | | | |
|
Resistance Level | $28.55 | 5 Day Moving Average | $26.78(-2.3%) | 10 Day Moving Average | $28.07(-6.79%) | 20 Day Moving Average | $28.55(-8.35%) | To recent high | -15.9% | To recent low | 41.5% | Market Cap | $3.314b | | | | TG Therapeutics, Inc. is a biopharmaceutical company, which engages in the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its product pipeline includes TG-1101, Ublituximab, and Umbralisib. The company was founded by Michael Sean Weiss and Laurence H. Shaw on May 18, 1993 and is headquartered in New York, NY. |